Figure 4
Figure 4. FBXL2 inhibits cell-cycle progression in transformed B-lymphoblastoid cells. (A) Immunoblotting showing levels of cyclins, CDKs, and negative control proteins, actin, and Erk after control (0) plasmid or ectopic FBXL2 expression. (B-C) FACS analysis in cells transfected with either empty plasmid or with increasing amount of FBXL2 plasmid. (D-E) Proliferation and viability studies of HCC1739 BL cells after FBXL2 overexpression. HCC1739 BL cells were transfected with FBXL2 for either 24 hours or 48 hours, cells were stained with trypan blue, and viable cells were analyzed by cell counting and graphed. n = 3 experiments, in control (C) #P < .01 versus empty plasmid, in panel D *P < .01 versus 0 hours, and in panel E *P < .01 versus control (CON).

FBXL2 inhibits cell-cycle progression in transformed B-lymphoblastoid cells. (A) Immunoblotting showing levels of cyclins, CDKs, and negative control proteins, actin, and Erk after control (0) plasmid or ectopic FBXL2 expression. (B-C) FACS analysis in cells transfected with either empty plasmid or with increasing amount of FBXL2 plasmid. (D-E) Proliferation and viability studies of HCC1739 BL cells after FBXL2 overexpression. HCC1739 BL cells were transfected with FBXL2 for either 24 hours or 48 hours, cells were stained with trypan blue, and viable cells were analyzed by cell counting and graphed. n = 3 experiments, in control (C) #P < .01 versus empty plasmid, in panel D *P < .01 versus 0 hours, and in panel E *P < .01 versus control (CON).

Close Modal

or Create an Account

Close Modal
Close Modal